Theralase Technologies Inc. (TLTFF OTCQB) stock market data APIs
$0.1933
0(0%)
as of August 6, 2026
Try our APIs with
free plan!
Theralase Technologies Inc. Financial Data Overview
Price chart is built with
Anychart
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Prev. Close
0.1933
Open
0.1933
High
0.1933
Low
0.1933
52 wk Range
0.1-0.31
Market Cap
56 178 K
Shares Outstanding
296 M
Revenue
858 K
EPS
-0.0028
Beta
0.587
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Theralase Technologies Inc. data using free add-ons & libraries
Get Theralase Technologies Inc. Fundamental Data
Theralase Technologies Inc. Fundamental data includes:
- Net Revenue: 858 K
- EBITDA: -3 552 798
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Theralase Technologies Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-28
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Theralase Technologies Inc. News
New
Theralase(R) closes $1.3M non-brokered private placement
* Theralase® Technologies (TLTFF [https://seekingalpha.com/symbol/TLTFF]) on Tuesday closed [https://seekingalpha.com/pr/20348622-theralase-r-closes-1_3-m-non-brokered-private-placement] a non-brok...
Theralase commences C$ 2M non-brokered private placement
* Theralase Technologies Inc (TLTFF [https://seekingalpha.com/symbol/TLTFF]) has commenced a non-brokered private placement of units of the company to raise up to C$ 2M. * In the offering, each un...
Theralase(R) Extends Warrants
Toronto, Ontario--(Newsfile Corp. - June 27, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light...
Theralase(R) Closes Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering ligh...
Get Theralase Technologies Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
